Loading company…
Riskpilot
← Back to search
Sign in
Get full access
VaccImmune Europe ApS
APS
In liquidation
CVR 39564432
Gammel Strandvej 18
Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100
Est. 2018
— employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2020
—
EBITDA margin
—
+269% vs 2019
Equity ratio
0.0%
Financial strength
Net profit 2020
DKK 18K
+247% vs 2019
EBITDA — year on year
DKK millions
0M
-0M
-1M
-1M
-1M
0M
2018
0M
0%
2019
0M
0%
2020
Key figures
Annual report 2020
Revenue
—
—
EBITDA
DKK 18K
+269%
Net profit
DKK 18K
+247%
Total assets
DKK 10K
+1035000%
Equity
DKK 1
+100%
Employees
—
—
Company information
Legal name
VaccImmune Europe ApS
CVR number
39564432
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
1. maj 2018
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Contact
Address
Gammel Strandvej 18
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Forskning og eksperimentel udvikling indenfor bioteknologi
Companies in Fredensborg
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
Income statement
DKK thousands
Item
2018
2019
2020
Revenue
—
—
—
Staff expenses
-0
-0
-0
EBITDA
-7
-10
18
Depreciation & amort.
-0
-0
-0
EBIT
-7
-10
18
Net financials
0
0
0
Profit before tax
-7
-10
18
Tax
-2
2
-0
Net profit
-6
-12
18
Balance sheet
DKK thousands
Item
2018
2019
2020
Total assets
2
0
10
Equity
-6
-18
0
Long-term debt
0
0
0
Short-term debt
7
18
10
Total debt
7
18
10
Financial ratios
5-year trend
EBITDA margin
1753800.0%
This company
15.8%
Market median
+11099900% vs market
2018
2020
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
2018
2020
Return on equity
1753800.0%
This company
18.4%
Market median
+9531422% vs market
2018
2020
Net profit margin
1753800.0%
This company
8.1%
Market median
+21651752% vs market
2018
2020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2018
2020
Debt / equity
10350.00×
This company
0.62×
Market median
-1669255% vs market
2018
2020
Annual reports & filings
Annual report 2020
Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via CVR / Virk · Period 2018-05-01 – 2018-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Former (3)
MA
Morten Albrechtsen
Chief Executive Officer
Chief Executive Officer
2018 – 2019
AR
Anders Rubinstein
Unofficial title
Unofficial title
2020 – 2021
PH
Per Horn
Chief Executive Officer
Chief Executive Officer
2019 – 2020
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
VaccImmune ApS
Company
100%
100%
2020
Vaccex, Inc.
Individual
100%
100%
2018
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of VaccImmune Europe ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Morten Albrechtsen
Chief Executive Officer
0 companies
Anders Rubinstein
Unofficial title
0 companies
Per Horn
Chief Executive Officer
0 companies